Sorry the previous competitor received $750 million from its commercial partner, so I am expecting that TIS should at least receive $500 million considering its monopoly position and potential market worth billions.
- Forums
- ASX - General
- the biotech sector
Sorry the previous competitor received $750 million from its...
Featured News
Featured News
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online